Introduction
============

Lung cancer was the leading cause of death from cancer in Europe in 2006, with 334,800 deaths (19.7% of total).[@b1-cmr-3-287] Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, representing more than 80% of lung cancer cases.[@b2-cmr-3-287]

Brain metastases (BMs) are a frequent complication of NSCLC, especially in patients with locally advanced disease.[@b3-cmr-3-287],[@b4-cmr-3-287] The addition of chemotherapy to radiation therapy (RT) reduces distant metastases and significantly improves survival.[@b5-cmr-3-287],[@b6-cmr-3-287] However, chemoradiotherapy is shown not to reduce the rate of BM,[@b5-cmr-3-287] but to be associated with increased rates of overall brain failure (21%--54%) and an increased incidence of the brain as the first site of relapse (15%--30%).[@b5-cmr-3-287]--[@b8-cmr-3-287] These findings emphasize the need for treatment specifically directed at brain micrometastases.

Prophylactic cranial irradiation (PCI) has been demonstrated to reduce the incidence or delay the onset of BM in patients with locally advanced NSCLC, after initial treatment in numerous selected nonrandomized and randomized studies.[@b3-cmr-3-287],[@b7-cmr-3-287],[@b9-cmr-3-287]--[@b16-cmr-3-287] Nevertheless, during the last decade only few studies assessed the clinical and epidemiological factors associated with high risk of BM appearance in NSCLC patients with locally advanced disease at diagnosis.[@b14-cmr-3-287],[@b17-cmr-3-287]--[@b20-cmr-3-287] In these studies, several factors such as duration of survival after diagnosis, performance status, chemotherapy regimens, age at diagnosis, sex, and lung cancer histotype and stage have been associated with the risk of BM development.

The authors of this paper hypothesized that among NSCLC patients of stage I--IV may exist a group of patients at high risk of presenting BM that may be protected using PCI. This group should be identified in order to serve as target for future studies of PCI application in NSCLC.

We performed an observational study in order to investigate the possible correlation of selected clinical and epidemiological factors with BM appearance in patients suffering from different histological subtypes of NSCLC stage I--IV.

Methods
=======

The study's cohort
------------------

We recruited 161 consecutive patients with a new diagnosis of NSCLC, between January 2003 and March 2009. Patients' selection criteria were as follows: confirmed diagnosis of NSCLC and appropriate staging. The sixth edition of the tumor--node--metastasis (TNM) classification was used.[@b21-cmr-3-287]

All patients were treated with surgery and/or chemotherapy and/or radiotherapy according to the current guidelines.[@b22-cmr-3-287],[@b23-cmr-3-287] They were evaluated every 3--6 months, depending on the curative or palliative nature of the initial treatment.

For each patient, the following variables were recorded at the time of diagnosis: age, sex, tobacco consumption, comorbidities, TNM status at diagnosis, tumor histotype, computed tomography (CT) scan features (central/peripheral location, side, lung lobe, size, cavitation, pleural effusion), and bronchoscopic findings. During the study period, the variables of patients with BM were registered and compared with those of patients without BM. All patients gave their informed consent, and the study was approved by the Ethics Committee of the "Sotiria" Chest Diseases Hospital, Athens.

Statistical analysis
--------------------

Mean values (and standard deviation \[SD\]) or median values (and interquartile range \[IR\]) were used to describe quantitative variables. For the comparison of quantitative variables without normal distribution between two groups, and between three or more different groups, the Mann-- Whitney test and Kruskal--Wallis test were used, respectively. To compare normal distributed quantitative variables between two groups and between three or more different groups, Student's *t*-test and analysis of variance test were used, respectively.

To control for type I errors, due to multiple comparisons, Bonferroni correction was used, by which the significance level is defined as 0.05/*k* (*k* = number of comparisons). Logistic regression analysis (stepwise method) was used in order to find independent factors associated with BM presentation. Odds ratios (ORs) and 95% confidence intervals (CIs) were computed from the results of logistic analysis. Kaplan--Meyer method was used to estimate survival curves. To compare survival curves, log rank tests were used. Statistical significance was set at 0.05, and all *P*-values are two tailed. For the statistical analysis, SPSS Statistics 17.0 (IBM Corporation, Somers, NY) and STATA 9.0 (Stata Corp, College Station, TX) programs were used.

Results
=======

Description of the cohort
-------------------------

Patient's characteristics are summarized in [Table 1](#t1-cmr-3-287){ref-type="table"}. Most of the patients were males (88.8%), with mean age (±SD) 65.1 ± 8.9 years and mean tobacco consumption (±SD) of 63.0 ± 31.0 pack-years.

Most of the tumors were located centrally (85.7%). Therefore, they were located within the range of fiber bronchoscopy, which revealed mainly mucosal or submucosal infiltration (67.7%). Most of the tumors were on the right lung (52.2%) and on the upper lobes (70.2%). The mean size (±SD) of the tumors, measured on CT scanners, was 48.1 ± 19.8 mm. Almost one-third (36.6%) were accompanied by pleural effusion at presentation. During the disease course, 37.3% of the patients presented lung, 36.6% bone, 23% liver, and 21.7% adrenal metastases.

BMs
---

BMs were presented in 24.2% of the patients. The median time (IR) of BM appearance was 12 (0--36) weeks from diagnosis. At the time of BM presentation, most of the patients were classified as T4 (42.9%) and N2 (43.5%) by the TNM classification. A total of 59% of the BMs were ≥2, mostly unilateral (53.8%).

The overall survival of the cohort was influenced by the presence of BM ([Figure 1](#f1-cmr-3-287){ref-type="fig"}). Survival time of the patients with BM was shorter compared with those without BM: 15.6 weeks (standard error \[SE\] = 1.9) versus 50.7 weeks (SE = 4.8, *P* \< 0.001). The hazard ratio, upon Cox model, for the presence of BM was 3.60 (95% CI 2.42--5.35, *P* \< 0.001).

The age of patients with BM was significantly lower compared with that of the patients without BM (60.8 ± 8.9 versus 66.5 ± 8.5, *P* \< 0.001) ([Table 2](#t2-cmr-3-287){ref-type="table"}). Furthermore, patients with BM had significantly higher pack-years consumption (75.9 ± 23.9 versus 58.9 ± 31.9, *P* = 0.003) and larger tumor size compared with patients without BM (size in mm: 55.1 ± 20.1 versus 45.9 ± 19.3, *P* = 0.012). The presence of BM was also correlated with the absence of lung (*P* \< 0.001), bone (*P* = 0.005), and adrenal (*P* = 0.046) metastases.

Patients with right-sided BM presented a significantly lower rate of arterial hypertension (16.7% versus 83.8%, *P* = 0.050) ([Table 3](#t3-cmr-3-287){ref-type="table"}). None of the patients with unilobar BM suffered from diabetes, compared with patients with multilobar (≥2 lobes) metastases (*P* = 0.015) ([Table 4](#t4-cmr-3-287){ref-type="table"}).

According to regression analysis, age, tobacco consumption in pack-years, and absence of lung or bone metastases represented independent prognostic factors for the appearance of BM ([Table 5](#t5-cmr-3-287){ref-type="table"}). In particular, an increase of age reduced the possibility of BM appearance (OR 0.91; 95% CI 0.87--0.96, *P* \< 0.001). Conversely, increasing cigarette consumption increased the possibility of BM appearance (OR 1.02; 95% CI 1.001--1.030, *P* = 0.006). Patients without lung and bone metastases had 76% and 70% higher possibility of presenting BM, respectively.

Discussion
==========

The main finding of this observational study was that younger NSCLC patients with high tobacco consumption, large tumor size, and absence of other metastases are at high risk of developing BMs during the course of their disease.

BM appearance and survival
--------------------------

Robnett et al reported that the timing of chest irradiation can influence the risk of brain recurrences: the rate of BM is 27% in patients receiving induction chemotherapy before thoracic RT compared with 15% in patients who are treated with concurrent chemoradiation.[@b17-cmr-3-287] The 2-year actuarial rate of BM is 39% versus 20%. The authors hypothesize that early aggressive locoregional and systemic treatment could better control regional disease, which in turn affects the development of brain relapses. In accordance with these findings, BMs presented in 39 out of 161 patients (24.2%) in this present study. The rate of BM is quite similar to the rate which has been previously reported by Robnett et al for patients who were not treated with concurrent chemoradiotherapy. The lack of a radiotherapy department in the "Sotiria" Chest Diseases Hospital renders impossible the application of concurrent chemoradiotherapy and therefore leads to the application of the sequential module.

Once diagnosed, BMs are mostly treated with wholeb-rain radiotherapy, having a response rate of 45%--81% in NSCLC.[@b24-cmr-3-287],[@b25-cmr-3-287] The overall survival of NSCLC patients with BM is poor, reported to be 3--6 months, despite medical treatment.[@b26-cmr-3-287] The overall survival of the patients in this present study with BM was also poor, approximately 4 months.

Patients who are at high risk of developing BM
----------------------------------------------

The delay of BM appearance is expected to improve prognosis of NSCLC patients. To achieve this, we need objective means to indicate patients at high risk for developing BM. Some studies have already been oriented towards this direction. Biologic agents like neuron specific enolase, carcinoembryonic antigen, serum sodium levels, or numerous molecular markers have been correlated with the development of BM and a shorter survival.[@b26-cmr-3-287]--[@b28-cmr-3-287]

Nevertheless, specific phenotypic characteristics may also serve as surrogate prognostic factors. Earlier studies correlated the presence of BM with advanced stage, NSCLC histotypes, delay of lung radiotherapy, younger age, and large tumor size.[@b28-cmr-3-287]--[@b32-cmr-3-287] However, few studies assessed in this regard tobacco consumption, comorbidities, CT scanner tumor characteristics, or the presence of metastases other than BMs.

### Age at diagnosis

Age \< 60 years was shown to be associated with an increased risk of BM.[@b30-cmr-3-287],[@b33-cmr-3-287],[@b34-cmr-3-287] In this present study, younger age (60.8 ± 8.9 years) was correlated with a higher possibility of BM appearance ([Table 2](#t2-cmr-3-287){ref-type="table"}). However, younger patients with BM present a better performance status and longer survival, while they may tolerate aggressive treatment better and are willing to accept a higher risk of toxicity than older patients.[@b26-cmr-3-287],[@b35-cmr-3-287]

### T and N status

T4 initial status was associated with increased risk of BM in a multivariate analysis of 305 patients with localized NSCLC.[@b30-cmr-3-287] The N2 status was found to be predictive of BM by Jacobs et al and by Tang et al.[@b36-cmr-3-287],[@b37-cmr-3-287]

In this study, lung tumor size was correlated with the appearance of BM (55.1 ± 20.1 cm) ([Table 2](#t2-cmr-3-287){ref-type="table"}). This finding is in agreement with the study of Mujoomdar et al.[@b31-cmr-3-287] However, no correlation was found with the T status itself. T status, as well as N status, has been correlated with BM outbreak in recent studies.[@b30-cmr-3-287],[@b31-cmr-3-287]

As is the case in the study of Shi et al, the authors of this present study found most of the primary tumors to be located in the right lung and in the upper lobes.[@b32-cmr-3-287] These frequent locations of lung tumor did not seem to correlate with the appearance of BM.[@b32-cmr-3-287] Central or peripheral location of primary lung tumor was not found to be correlated to BM, which is in agreement with the study of Mujoomdar et al.[@b31-cmr-3-287]

### M status

Previous studies speculate that the spread of lung cancer to the thoracic lymphatic system and to the brain could also relate to the presence of distant metastatic disease in other organs.[@b31-cmr-3-287] So far, no study has confirmed this hypothesis. On the contrary, in this present study, appearance of BM was correlated with the absence of metastases in other organs, like lung, bone, and adrenal glands. Except adrenal metastases,[@b27-cmr-3-287] synchronous metastases in other organs have not been correlated with median survival, probably as a result of already poor prognosis of the BM.[@b26-cmr-3-287]

### Tobacco consumption

Smoking status has already been correlated with poor prognosis and shorter overall survival in lung cancer patients,[@b18-cmr-3-287] but no correlation was found with BM. In this study's cohort, high tobacco consumption (75.9 ± 23.9 pack-years) was correlated with the outbreak of BM.

### NSCLC histological subtype

In previous studies, non-squamous lung cancer, mainly lung adenocarcinoma, showed higher prevalence of BM development.[@b30-cmr-3-287]--[@b32-cmr-3-287] In this study, no correlation was found between NSCLC histotype and BM appearance. This discordance is probably a result of the small number of allocated groups and the relatively large number of unspecified NSCLC tumors in the present study.

PCI
---

Prophylactic cranial irradiation (PCI) has been demonstrated to reduce the incidence or delay the onset of BM in patients with locally advanced NSCLC after initial treatment.[@b3-cmr-3-287],[@b7-cmr-3-287],[@b9-cmr-3-287]--[@b16-cmr-3-287] Thus, identification of risk population for BM development is pertinent. Specific phenotypes of patients at higher risk for BM development could serve as candidates of PCI and could allow early intervention, which seems more promising than the palliative approach.

Limitations
-----------

The patients in this current study were treated with sequential rather than concurrent chemoradiotherapy despite the current treatment guidelines. This limitation of the study is due to the lack of a radiotherapy department in the "Sotiria" Chest Diseases Hospital.

The pathologic data lack molecular markers, which could be related to the overall survival as is the case in many recent studies. In fact, during the study period, molecular data were not available.

Implications
------------

This study records the deleterious effect of BMs on NSCLC patient survival, enriches the high risk profile with more features, and contributes to the discussion of pathophysiologic mechanisms underlying the brain involvement in NSCLC. More studies are needed in order to elucidate these issues.

Conclusion
==========

Younger NSCLC patients with high tobacco consumption, large tumor size, and absence of other metastases (lung, bones, adrenal metastases) are at high risk of BM appearance during the course of NSCLC and may be candidates for PCI early in the course of their disease. Apart from genome-based studies, phenotype-based studies may contribute to future lung cancer therapy.
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###### 

Patient- and disease-related characteristics

  Characteristic                                                                 n (%)
  ------------------------------------------------------------------------------ ----------------------
  **Patient-related variables**                                                  
  Sex                                                                            
  Male/female                                                                    143 (88.8)/18 (11.2)
  Age                                                                            
  Mean ± SD                                                                      65.1 ± 8.9
  Pack-years                                                                     
  Mean ± SD                                                                      63.0 ± 31.0
  COPD                                                                           
  No/yes                                                                         89 (55.3)/72 (44.7)
  Arterial hypertension                                                          
  No/yes                                                                         98 (60.9)/63 (39.1)
  Coronary disease                                                               
  No/yes                                                                         132 (82.0)/29 (18.0)
  Diabetes mellitus                                                              
  No/yes                                                                         136 (84.5)/25 (15.5)
  Gastritis/ulcer                                                                
  No/yes                                                                         138 (85.7)/23 (14.3)
  Hypothyroidism                                                                 
  No/yes                                                                         154 (95.7)/7 (4.3)
  Other comorbidity                                                              
  No/yes                                                                         130 (80.7)/31 (19.3)
  **Disease-related variables**                                                  
  Histotype                                                                      
  Non-differentiated NSCLC                                                       49 (30.4)
  Squamous                                                                       49 (30.4)
  Adenocarcinoma                                                                 59 (36.6)
  Large cell carcinoma                                                           4 (2.6)
  Location                                                                       
  Central/peripheral                                                             138 (85.7)/23 (14.3)
  Bronchoscopic findings                                                         
  Mass                                                                           36 (22.4)
  Infiltration                                                                   109 (67.7)
  None                                                                           16 (9.9)
  Lung tumor side                                                                
  Right/left                                                                     84 (52.2)/77 (47.8)
  Lung tumor lobe                                                                
  Upper                                                                          113 (70.2)
  Middle                                                                         8 (5.0)
  Inferior                                                                       40 (24.8)
  Lung tumor size                                                                
  Mean ± SD                                                                      48.1 ± 19.8
  Other tumor characteristics                                                    
  Pleural effusion                                                               59 (36.6)
  Cavitation                                                                     12 (7.5)
  None                                                                           90 (55.9)
  T classification (brain metastases)[a](#tfn1-cmr-3-287){ref-type="table-fn"}   
  T~1~/T~2~                                                                      13 (8.1)/55 (34.2)
  T~3~/T~4~                                                                      24 (14.9)/69 (42.9)
  N classification (brain metastases)[a](#tfn1-cmr-3-287){ref-type="table-fn"}   
  N~0~/N~1~                                                                      38 (23.6)/16 (9.9)
  N~2~/N~3~                                                                      70 (43.5)/37 (23.0)
  Lung metastasis                                                                
  No/yes                                                                         101 (62.7)/60 (37.3)
  Bones metastasis                                                               
  No/yes                                                                         102 (63.4)/59 (36.6)
  Liver metastasis                                                               
  No/yes                                                                         124 (77.0)/37 (23.0)
  Adrenal metastasis                                                             
  No/yes                                                                         126 (78.3)/35 (21.7)
  Other metastasis                                                               
  No/yes                                                                         144 (89.4)/17 (10.6)
  Metastasis brain                                                               
  No/yes                                                                         122 (75.8)/39 (24.2)
  Diagnosis to brain metastases time (weeks)                                     
  Median (IR)                                                                    12 (0--36)
  Number of brain metastases                                                     
  0/1                                                                            122 (75.8)/16 (9.9)
  2/\>2                                                                          6 (3.7)/17 (10.6)
  Brain metastasis side                                                          
  Right                                                                          12 (30.8)
  Left                                                                           9 (23.0)
  Bilateral                                                                      18 (46.2)
  Brain metastasis lobe                                                          
  Frontal                                                                        9 (23.1)
  Parietal                                                                       9 (23.1)
  Occipital                                                                      1 (2.6)
  Cerebellum                                                                     2 (5.1)
  ≥2                                                                             18 (46.2)

**Note:** TNM (tumor--node--metastasis) classification.[@b21-cmr-3-287]

**Abbreviations:** COPD, chronic obstructive pulmonary disease; IR, interquartile range; NSCLC, non-small cell lung cancer; SD, standard deviation.

###### 

Correlation of brain metastases with patient- and disease-related features (univariate analysis)

  Feature                                                                        Brain metastases   *P* χ^2^ test   
  ------------------------------------------------------------------------------ ------------------ --------------- --------------------------------------------------
  **Patient-related variables**                                                                                     
  Sex                                                                                                               
  Male/female                                                                    108/14             35/4            0.833
  Age                                                                                                               
  Mean ± SD                                                                      66.5 ± 8.5         60.8 ± 8.9      \<0.001[a](#tfn3-cmr-3-287){ref-type="table-fn"}
  Pack-years                                                                                                        
  Mean ± SD                                                                      58.9 ± 31.9        75.9 ± 23.9     0.003[a](#tfn3-cmr-3-287){ref-type="table-fn"}
  COPD                                                                                                              
  No/yes                                                                         68/54              21/18           0.836
  Arterial hypertension                                                                                             
  No/yes                                                                         77/45              21/18           0.302
  Diabetes mellitus                                                                                                 
  No/yes                                                                         102/20             34/5            0.592
  Coronary disease                                                                                                  
  No/yes                                                                         98/24              34/5            0.332
  Hypothyroidism                                                                                                    
  No/yes                                                                         118/4              36/3            0.361[b](#tfn4-cmr-3-287){ref-type="table-fn"}
  Gastritis/ulcer                                                                                                   
  No/yes                                                                         105/17             33/6            0.822
  Other comorbidity                                                                                                 
  No/yes                                                                         97/25              33/6            0.481
  **Disease-related variables**                                                                                     
  Histotype                                                                                                         
  Non-differentiated NSCLC                                                       33                 16              0.586[b](#tfn4-cmr-3-287){ref-type="table-fn"}
  Squamous                                                                       38                 11              
  Adenocarcinoma                                                                 48                 11              
  Large cell carcinoma                                                           3                  1               
  Location                                                                                                          
  Central/peripheral                                                             105/17             33/6            0.822
  Bronchoscopic findings                                                                                            
  Mass                                                                           29                 7               0.151
  Infiltration                                                                   78                 31              
  None                                                                           15                 1               
  Lung tumor side                                                                                                   
  Right/left                                                                     62/60              22/17           0.543
  Lung tumor lobe                                                                                                   
  Upper                                                                          86                 27              0.657
  Middle                                                                         5                  3               
  Inferior                                                                       31                 9               
  Lung tumor size                                                                                                   
  Mean ± SD                                                                      45.9 ± 19.3        55.1 ± 20.1     0.012[a](#tfn3-cmr-3-287){ref-type="table-fn"}
  Other tumor characteristics                                                                                       
  Pleural effusion                                                               48                 11              0.399
  Cavitation                                                                     8                  4               
  None                                                                           66                 24              
  T classification (brain metastases)[c](#tfn5-cmr-3-287){ref-type="table-fn"}                                      
  T~1~/T~2~                                                                      10/37              3/18            0.138
  T~3~/T~4~                                                                      22/53              2/16            
  N classification (brain metastases)[c](#tfn5-cmr-3-287){ref-type="table-fn"}                                      
  N~0~/N~1~                                                                      29/10              9/6             0.550
  N~2~/N~3~                                                                      53/30              17/7            
  Lung metastasis                                                                                                   
  No/yes                                                                         67/55              34/5            \<0.001
  Bone metastasis                                                                                                   
  No/yes                                                                         70/52              32/7            0.005
  Liver metastasis                                                                                                  
  No/yes                                                                         91/31              33/6            0.195
  Adrenal                                                                                                           
  No/yes                                                                         91/31              35/4            0.046
  Other metastasis                                                                                                  
  No/yes                                                                         107/15             37/2            0.205

**Notes:** Student's *t*-test;

Fisher's exact test;

TNM (tumor--node--metastasis) classification.[@b21-cmr-3-287]

**Abbreviations:** COPD, chronic obstructive pulmonary disease; NSCLC, non-small cell lung cancer; SD, standard deviation.

###### 

Univariate analysis of brain metastases side

                                               Metastasis side   *P* χ^2^ test                 
  -------------------------------------------- ----------------- --------------- ------------- ------------------------------------------------
  **Patient-related variables**                                                                
  Sex                                                                                          
  Male/female                                  11/1              9/0             15/3          0.546
  Age                                                                                          
  Mean ± SD                                    57.7 ± 8.3        62.6 ± 9.9      61.9 ± 8.7    0.349[a](#tfn7-cmr-3-287){ref-type="table-fn"}
  Pack-years                                                                                   
  Mean ± SD                                    80.8 ± 20.2       84.0 ± 19.6     68.6 ± 26.8   0.202[a](#tfn7-cmr-3-287){ref-type="table-fn"}
  COPD                                                                                         
  No/yes                                       6/6               5/4             10/8          1.000
  Arterial hypertension                                                                        
  No/yes                                       10/2              4/5             7/11          0.050
  Coronary disease                                                                             
  No/yes                                       12/0              9/0             13/5          0.054
  Diabetes mellitus                                                                            
  No/yes                                       11/1              9/0             14/4          0.406
  Gastritis/ulcer                                                                              
  No/yes                                       12/0              7/2             17/1          0.216
  Hypothyroidism                                                                               
  No/yes                                       12/0              6/3             15/3          0.063
  Other comorbidity                                                                            
  No/yes                                       11/1              7/2             15/3          0.740
  **Disease-related variables**                                                                
  Histotype                                                                                    
  Non-differentiated NSCLC                     6                 2               7             0.194
  Squamous                                     2                 4               5             
  Adenocarcinoma                               3                 3               6             
  Large cell carcinoma                         1                 0               0             
  Location                                                                                     
  Central/peripheral                           10/2              8/1             15/3          1.000
  Diagnosis to brain metastases time (weeks)                                                   
  Median (IR)                                  18 (4--40)        0 (0--26)       14 (0--36)    0.632[b](#tfn8-cmr-3-287){ref-type="table-fn"}

**Notes:** Analysis of variance;

Kruskall--Wallis test.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; IR, interquartile range; NSCLC, non-small cell lung cancer; SD, standard deviation.

###### 

Univariate analysis of brain metastases lobes

                                               Metastasis lobe   *P* Fisher's exact test   
  -------------------------------------------- ----------------- ------------------------- -------------------------------------------------
  **Patient-related variables**                                                            
  Sex                                                                                      
  Male/female                                  19/2              16/2                      1.000
  Age                                                                                      
  Mean ± SD                                    61.0 ± 9.5        60.6 ± 8.3                0.891[a](#tfn10-cmr-3-287){ref-type="table-fn"}
  Pack-years                                                                               
  Mean ± SD                                    79.1 ± 19.8       72.2 ± 28.0               0.377[a](#tfn10-cmr-3-287){ref-type="table-fn"}
  COPD                                                                                     
  No/yes                                       12/9              9/9                       0.656[b](#tfn11-cmr-3-287){ref-type="table-fn"}
  Arterial hypertension                                                                    
  No/yes                                       13/8              8/10                      0.276[b](#tfn11-cmr-3-287){ref-type="table-fn"}
  Diabetes mellitus                                                                        
  No/yes                                       21/0              13/5                      0.015
  Coronary disease                                                                         
  No/yes                                       20/1              14/4                      0.104
  Hypothyroidism                                                                           
  No/yes                                       19/2              17/1                      1.000
  Gastritis/ulcer                                                                          
  No/yes                                       18/3              15/3                      1.000
  Other comorbidity                                                                        
  No/yes                                       17/4              16/2                      0.667
  **Disease-related variables**                                                            
  Histotype                                                                                
  Non-differentiated NSCLC                     7                 8                         0.088
  Squamous                                     5                 6                         
  Adenocarcinoma                               8                 4                         
  Large cell carcinoma                         1                 0                         
  Location                                                                                 
  Central/peripheral                           17/4              16/2                      0.667
  Diagnosis to brain metastases time (weeks)                                               
  Median (IR)                                  17 (0--32)        8 (0--36)                 0.922[c](#tfn12-cmr-3-287){ref-type="table-fn"}

**Notes:** Student's *t*-test;

Pearson's χ^2^ test;

Mann--Whitney test.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; IR, interquartile range; NSCLC, non-small cell lung cancer; SD, standard deviation.

###### 

Correlation of brain metastases with patient- and disease-related features (multivariate analysis)

  Variable          Odds ratio                                       95%    CI     *P*
  ----------------- ------------------------------------------------ ------ ------ ---------
  Age               0.91                                             0.87   0.96   \<0.001
  Pack-years        1.02                                             1.01   1.03   0.006
  Lung metastasis                                                                  
  No                1.00[a](#tfn14-cmr-3-287){ref-type="table-fn"}                 
  Yes               0.24                                             0.08   0.69   0.008
  Bone metastasis                                                                  
  No                1.00[a](#tfn14-cmr-3-287){ref-type="table-fn"}                 
  Yes               0.30                                             0.11   0.81   0.018

**Note:** Represents referral class.
